GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Shiller PE Ratio

Cyclacel Pharmaceuticals (STU:UXI) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cyclacel Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Shiller PE Ratio Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cyclacel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cyclacel Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Shiller PE Ratio falls into.



Cyclacel Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cyclacel Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Cyclacel Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.088/131.7762*131.7762
=-2.088

Current CPI (Mar. 2024) = 131.7762.

Cyclacel Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -582.914 100.560 -763.868
201409 -614.594 100.428 -806.439
201412 -613.118 99.070 -815.530
201503 -632.019 99.621 -836.018
201506 -318.087 100.684 -416.316
201509 -253.935 100.392 -333.321
201512 -330.481 99.792 -436.401
201603 -280.176 100.470 -367.477
201606 -269.670 101.688 -349.462
201609 -229.878 101.861 -297.390
201612 -196.236 101.863 -253.864
201703 -106.590 102.862 -136.552
201706 -133.500 103.349 -170.220
201709 -229.047 104.136 -289.843
201712 -44.056 104.011 -55.816
201803 -29.196 105.290 -36.541
201806 -41.088 106.317 -50.927
201809 -46.278 106.507 -57.258
201812 -44.829 105.998 -55.731
201903 -36.772 107.251 -45.181
201906 -28.276 108.070 -34.479
201909 -30.917 108.329 -37.609
201912 -37.800 108.420 -45.943
202003 -20.091 108.902 -24.311
202006 -7.726 108.767 -9.360
202009 -5.985 109.815 -7.182
202012 -16.522 109.897 -19.811
202103 -6.300 111.754 -7.429
202106 -6.972 114.631 -8.015
202109 -6.885 115.734 -7.839
202112 -7.169 117.630 -8.031
202203 -5.720 121.301 -6.214
202206 -6.527 125.017 -6.880
202209 -6.515 125.227 -6.856
202212 -8.496 125.222 -8.941
202303 -6.538 127.348 -6.765
202306 -6.092 128.729 -6.236
202309 -6.746 129.860 -6.846
202312 -5.713 129.419 -5.817
202403 -2.088 131.776 -2.088

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cyclacel Pharmaceuticals  (STU:UXI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cyclacel Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals (STU:UXI) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (STU:UXI) Headlines

No Headlines